Solomon G D
Department of General Internal Medicine, Cleveland Clinic Foundation 44195, USA.
Semin Pediatr Neurol. 1995 Jun;2(2):165-77. doi: 10.1016/s1071-9091(05)80027-0.
Migraine is a common and disabling disease of uncertain pathogenesis. Research on the trigeminovascular system, serotonin receptors, and substance P have provided clues to improving the pharmacotherapy of this disorder. Selective serotonin agonists, such as sumatriptan, dihydroergotamine, ergotamine tartrate, nonsteroidal anti-inflammatory drugs (NSAIDS), isometheptene mucate, and phenothiazines are useful to treat acute attacks. Prophylactic agents include beta-blockers, calcium channel blockers, NSAIDs, antidepressants, and valproate. The addition of several new agents for the acute and prophylactic therapy of migraine has improved the outlook for this debilitating disorder.
偏头痛是一种常见的、病因不明的致残性疾病。对三叉神经血管系统、5-羟色胺受体和P物质的研究为改善这种疾病的药物治疗提供了线索。选择性5-羟色胺激动剂,如舒马曲坦、双氢麦角胺、酒石酸麦角胺、非甾体抗炎药(NSAIDs)、樟柳碱和吩噻嗪,对治疗急性发作有效。预防性药物包括β受体阻滞剂、钙通道阻滞剂、NSAIDs、抗抑郁药和丙戊酸盐。几种用于偏头痛急性和预防性治疗的新药的加入改善了这种使人衰弱的疾病的治疗前景。